<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tamoxifen</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00675</strong>&#160; (APRD00123)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>One of the selective estrogen receptor modulators (<span class="caps">SERM</span>) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00675/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00675/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00675.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00675.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00675.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00675.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00675.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00675">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Tamoxifen</td><td>German</td><td>INN</td></tr><tr><td>Tamoxif&#232;ne</td><td>French</td><td>INN</td></tr><tr><td>Tamoxifene</td><td>Italian</td><td>DCIT</td></tr><tr><td>Tamoxifeno</td><td>Spanish</td><td>INN</td></tr><tr><td>Tamoxifenum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Tamoxifen Citrate</strong>
          <div class="cas">54965-24-1</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000168/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000168/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: FQZYTYWMLGAPFJ-OQKDUQJOSA-N</li>
              <li>Monoisotopic Mass: 563.251917165</li>
              <li>Average Mass: 563.6381</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000168">DBSALT000168</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Adifen</td><td>Medicamerc</td></tr><tr><td>Adopan</td><td>Sawai Seiyaku</td></tr><tr><td>Bilem</td><td>Teva Int'l</td></tr><tr><td>Caditam</td><td>Cadila</td></tr><tr><td>Citofen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Crisafeno</td><td>LKM</td></tr><tr><td>Doctamoxifene</td><td>Docpharma</td></tr><tr><td>Ebefen</td><td>Ebewe</td></tr><tr><td>Fenahex</td><td>Sandoz</td></tr><tr><td>Genox</td><td>Merck Serono</td></tr><tr><td>Gynatam</td><td>Biogalenic</td></tr><tr><td>Istubal</td><td>AstraZeneca</td></tr><tr><td>Mammonex</td><td>CP Pharmaceuticals</td></tr><tr><td>Neophedan</td><td>Aspen Pharmacare</td></tr><tr><td>Noltam</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nolvadex</td><td>AstraZeneca</td></tr><tr><td>Nolvadex-D</td><td>AstraZeneca</td></tr><tr><td>Novofen</td><td>Remedica</td></tr><tr><td>Oncomox</td><td>Sun</td></tr><tr><td>PMS-Tamoxifen</td><td>Pharmascience</td></tr><tr><td>Soltamox</td><td>Dara Biosciences </td></tr><tr><td>Tadex</td><td>Orion</td></tr><tr><td>Tamifen</td><td>Medochemie</td></tr><tr><td>Tamizam</td><td>Mithra</td></tr><tr><td>Tamofen</td><td>Sanofi-Aventis</td></tr><tr><td>Tamoneprin</td><td>Actavis</td></tr><tr><td>Tamoplex</td><td>Pharmachemie</td></tr><tr><td>Tamoxen</td><td>Ascent</td></tr><tr><td>Tamoxilon</td><td>Celon</td></tr><tr><td>Tamtero</td><td>Hetero</td></tr><tr><td>Tecnotax</td><td>Zodiac</td></tr><tr><td>Tomifen</td><td>Alkem</td></tr><tr><td>Valodex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zemide</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents-hormonal">Antineoplastic Agents, Hormonal</a></li>
<li><a href="/mesh/bone-density-conservation-agents">Bone Density Conservation Agents</a></li>
<li><a href="/mesh/estrogen-antagonists">Estrogen Antagonists</a></li>
<li><a href="/mesh/selective-estrogen-receptor-modulators">Selective Estrogen Receptor Modulators</a></li></ul></td></tr><tr><th>CAS number</th><td>10540-29-1</td></tr><tr><th>Weight</th><td>Average: 371.5146<br>Monoisotopic: 371.224914555</td></tr><tr><th>Chemical Formula</th><td>C<sub>26</sub>H<sub>29</sub>NO</td></tr><tr><th>InChI Key</th><td>NKANXQFJJICGDU-QPLCGJKRSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Phenylpropanoids and Polyketides</td></tr><tr><th>Class</th><td>Stilbenes</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Stilbenes</td></tr><tr><th>Alternative parents</th><td>Diphenylmethanes; Phenylpropenes; Phenol Ethers; Alkyl Aryl Ethers; Tertiary Amines; Polyamines</td></tr><tr><th>Substituents</th><td>phenylpropene; phenol ether; alkyl aryl ether; benzene; tertiary amine; polyamine; ether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups  to a phenyl ring lead to stilbenoids.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Tamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ. </td></tr><tr><th>Pharmacodynamics</th><td>Tamoxifen belongs to a class of drugs called selective estrogen receptor modulators (SERMs), which have both estrogenic and antiestrogenic effects. Tamoxifen has the same nucleus as diethylstilbestrol but possesses an additional side chain (<i>trans</i> isomer) which accounts for its antiestrogenic activity.</td></tr><tr><th>Mechanism of action</th><td>Tamoxifen is a nonsteroidal agent that binds to estrogen receptors (ER), inducing a conformational change in the receptor. This results in a blockage or change in the expression of estrogen dependent genes. The prolonged binding of tamoxifen to the nuclear chromatin of these results in reduced DNA polymerase activity, impaired thymidine utilization, blockade of estradiol uptake, and decreased estrogen response. It is likely that tamoxifen interacts with other coactivators or corepressors in the tissue and binds with different estrogen receptors, ER-alpha or ER-beta, producing both estrogenic and antiestrogenic effects.</td></tr><tr><th>Absorption</th><td>When a single oral dose of 20 mg is given, the average peak plasma concentration (Cmax) is 40 ng/mL which occurred approximately 5 hours after dosing (Tmax). The Cmax of N-desmethyl tamoxifen is 15 ng/mL. Steady-state concentrations for tamoxifen is achieved in 4 weeks, while steady-state concentrations for N-desmethyl tamoxifen is achieved in 8 weeks. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Tamoxifen is extensively metabolized after oral administration. N-Desmethyl-tamoxifen is the major metabolite found in plasma. N-Desmethyl-tamoxifen's activity is similar to tamoxifen. 4-hydroxy-tamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. 4-Hydroxy-tamoxifen formation is catalyzed mainly by cytochrome P450 (CYP) 2D6, and also by CYP2C9 and 3A4. At high tamoxifen concentrations, CYP2B6 also catalyzes 4-hydroxylation of the parent drug. 4-Hydroxy-tamoxifen possesses 30- to 100-times greater affinity for the estrogen receptor and 30- to 100-times greater potency at inhibiting estrogen-dependent cell proliferation compared to tamoxifen. It is also metabolized by flavin monooxygenases FMO1 and FMO3 to form tamoxifen-N-oxide. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Tamoxifen</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00029">N-Desmethyltamoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/29">Details</a></td></tr><tr><td>Tamoxifen</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0001111" target="_blank">Cytochrome P450 1B1</a></li></ul></td><td><a href="/metabolites/DBMET00030">4-Hydroxytamoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/30">Details</a></td></tr><tr><td>Tamoxifen</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li></ul></td><td><a href="/metabolites/DBMET00031">3-Hydroxytamoxifen (Droloxifene)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/31">Details</a></td></tr><tr><td>Tamoxifen</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003609" target="_blank">Dimethylaniline monooxygenase [N-oxide-forming] 1</a></li>
<li><a href="/biodb/bio_entities/BE0003606" target="_blank">Dimethylaniline monooxygenase [N-oxide-forming] 3</a></li></ul></td><td><a href="/metabolites/DBMET00032">Tamoxifen N-oxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/32">Details</a></td></tr><tr><td>Tamoxifen</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET00796">Alpha-hydroxytamoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/817">Details</a></td></tr><tr><td>Tamoxifen</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003544" target="_blank">UDP-glucuronosyltransferase 1-4</a></li></ul></td><td><a href="/metabolites/DBMET01004">Tamoxifen-N-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1027">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00030">4-Hydroxytamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET01044">Endoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1095">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00796">Alpha-hydroxytamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00794">Alpha-hydroxy-tamoxifen-O-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1096">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00030">4-Hydroxytamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000927" target="_blank">Sulfotransferase 1A1</a></li>
<li><a href="/biodb/bio_entities/BE0000886" target="_blank">Bile salt sulfotransferase</a></li>
<li><a href="/biodb/bio_entities/BE0000951" target="_blank">Estrogen sulfotransferase</a></li></ul></td><td><a href="/metabolites/DBMET00737">4-hydroxytamoxifen sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1098">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00030">4-Hydroxytamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003544" target="_blank">UDP-glucuronosyltransferase 1-4</a></li>
<li><a href="/biodb/bio_entities/BE0003677" target="_blank">UDP-glucuronosyltransferase 1-3</a></li></ul></td><td><a href="/metabolites/DBMET00738">4-hydroxytamoxifen-N-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1099">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00030">4-Hydroxytamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003682" target="_blank">UDP-glucuronosyltransferase 1-8</a></li>
<li><a href="/biodb/bio_entities/BE0003678" target="_blank">UDP-glucuronosyltransferase 1-10</a></li>
<li><a href="/biodb/bio_entities/BE0004696" target="_blank">UDP-glucuronosyltransferase 2B15</a></li>
<li><a href="/biodb/bio_entities/BE0003544" target="_blank">UDP-glucuronosyltransferase 1-4</a></li>
<li><a href="/biodb/bio_entities/BE0003679" target="_blank">UDP-glucuronosyltransferase 2B7</a></li></ul></td><td><a href="/metabolites/DBMET00739">4-hydroxytamoxifen-O-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1100">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00029">N-Desmethyltamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET01060">alpha-Hydroxy-N-desmethyltamoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1102">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00029">N-Desmethyltamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET01044">Endoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1103">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01044">Endoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000927" target="_blank">Sulfotransferase 1A1</a></li></ul></td><td><a href="/metabolites/DBMET00849">Endoxifen sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1107">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01044">Endoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00963">Norendoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1109">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01044">Endoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003678" target="_blank">UDP-glucuronosyltransferase 1-10</a></li>
<li><a href="/biodb/bio_entities/BE0003682" target="_blank">UDP-glucuronosyltransferase 1-8</a></li>
<li><a href="/biodb/bio_entities/BE0003679" target="_blank">UDP-glucuronosyltransferase 2B7</a></li></ul></td><td><a href="/metabolites/DBMET00848">Endoxifen O-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1110">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00029">N-Desmethyltamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0003612" target="_blank">Cytochrome P450 3A7</a></li></ul></td><td><a href="/metabolites/DBMET00441">N-Didesmethyl-tamoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1247">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00030">4-Hydroxytamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00442">3,4-Dihydroxy-tamoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1248">Details</a></td></tr><tr><td>Tamoxifen</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET01130">4'-Hydroxytamoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1249">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00030">4-Hydroxytamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0001111" target="_blank">Cytochrome P450 1B1</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET01131">cis-4-Hydroxytamoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1250">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00032">Tamoxifen N-oxide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET01132">alpha-Hydroxytamoxifen N-oxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1251">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00796">Alpha-hydroxytamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET01132">alpha-Hydroxytamoxifen N-oxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1252">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00796">Alpha-hydroxytamoxifen</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01060">alpha-Hydroxy-N-desmethyltamoxifen</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1253">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>65% of the dose was excreted from the body over 2 weeks in which fecal excretion was the primary route of elimination. Tamoxifen is excreted mainly as polar conjugates, with unchanged drug and unconjugated metabolites accounting for less than 30% of the total fecal radioactivity. </td></tr><tr><th>Half life</th><td>The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days. </td></tr><tr><th>Clearance</th><td><p>Clearance (CL/F) as body weight adjusted in female pediatric patients was approximately 2.3-fold higher than in female breast cancer patients.</p></td></tr><tr><th>Toxicity</th><td>Signs observed at the highest doses following studies to determine LD<sub>50</sub> in animals were respiratory difficulties and convulsions.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Tamoxifen Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00471?highlight%5Bcompounds%5D%5B%5D=DB00675&amp;highlight%5Bproteins%5D%5B%5D=DB00675">SMP00471</a></td></tr><tr><td>Tamoxifen Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00606?highlight%5Bcompounds%5D%5B%5D=DB00675&amp;highlight%5Bproteins%5D%5B%5D=DB00675">SMP00606</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytochrome P450 2D6<br>Gene symbol: CYP2D6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P10635" target="_blank">P10635 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs3892097" target="_blank">rs3892097 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2D6*4</td><td>A Allele, homozygote</td><td>Poor response to drug treatment, shorter time to relapse</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/17115111" target="_blank" title="Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007 Jan;101(1):113-21. Epub 2006 Nov 18.">17115111 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Coagulation factor V<br>Gene symbol: F5<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P12259" target="_blank">P12259 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs6025" target="_blank">rs6025 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A allele</td><td>Breast cancer patients taking tamoxifen as part of treatment regimine are more likely to experience a thromboembolic event.</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/20554945" target="_blank" title='# Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett ED, Kimmick G, Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N: Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010 Jul 7;102(13):942-9. doi: 10.1093/jnci/djq211. Epub 2010 Jun 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20554945'>20554945 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.997</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.5838</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7718</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8564</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6225</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.6715</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8918</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7407</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.8535</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9072</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8448</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5054</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6058
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9048
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.9882 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.7402
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6898
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Rosemont group ltd</li>
<li>Astrazeneca pharmaceuticals lp</li>
<li>Aegis pharmaceuticals inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mylan pharmaceuticals inc</li>
<li>Pharmachemie bv</li>
<li>Roxane laboratories inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Watson laboratories inc</li>
<li>Watson laboratories inc florida</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Egis Pharmaceuticals Public Ltd. Co.</li>
<li><a href="http://www.iic.co.th">Imperial Chemical Industrial Ltd.</a></li>
<li>Innovative Manufacturing and Distribution Services Inc.</li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Wampole Laboratories</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Oral</td><td>10 mg/5 mL</td></tr><tr><td>Tablet</td><td>Oral</td><td>10 mg, 20 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Tamoxifen citrate powder</td><td>50.03USD</td><td>g</td></tr><tr><td>Nolvadex 20 mg tablet</td><td>4.46USD</td><td>tablet</td></tr><tr><td>Tamoxifen Citrate 20 mg tablet</td><td>3.94USD</td><td>tablet</td></tr><tr><td>Tamoxifen 20 mg tablet</td><td>3.79USD</td><td>tablet</td></tr><tr><td>Nolvadex 10 mg tablet</td><td>2.04USD</td><td>tablet</td></tr><tr><td>Tamoxifen Citrate 10 mg tablet</td><td>1.97USD</td><td>tablet</td></tr><tr><td>Tamoxifen 10 mg tablet</td><td>1.89USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6127425</td><td>1998-06-26</td><td>2018-06-26</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>97 &#176;C</td><td>PhysProp</td></tr><tr><td>water solubility</td><td>0.000167 mg/mL at 25 &#176;C</td><td>MEYLAN,WM et al. (1996)</td></tr><tr><td>logP</td><td>7.1</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>1.02e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>5.93</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>6.35</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-5.6</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>8.76</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>12.47</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>8</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>128.43</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>44.19</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Chengjian Mao, &#8220;Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells.&#8221; U.S. Patent US20030199022, issued October 23, 2003.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=20030199022&amp;tbm=pts" target="_blank">US20030199022 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Jordan VC: Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol. 2006 Jan;147 Suppl 1:S269-76. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16402113">Pubmed</a></li>
	<li>Jordan VC: Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol. 1993 Oct;110(2):507-17. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8242225">Pubmed</a></li>
	<li>Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the <span class="caps">ATAC</span> (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years&#8217; adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7;365(9453):60-2. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15639680">Pubmed</a></li>
	<li>Steiner AZ, Terplan M, Paulson RJ: Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum Reprod. 2005 Jun;20(6):1511-5. Epub 2005 Apr 21. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15845599">Pubmed</a></li>
	<li>van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG: Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med. 2006 Jan 17;144(2):101-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16418409">Pubmed</a></li>
	<li><span class="caps">FDA</span> label</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00966" target="_blank">D00966 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07108" target="_blank">C07108 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2733526" target="_blank">2733526 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505515" target="_blank">46505515 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.2015313.html" target="_blank">2015313 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=20607" target="_blank">20607 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=9396" target="_blank">9396 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL83" target="_blank">CHEMBL83 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000108" target="_blank">DAP000108 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451581" target="_blank">PA451581 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=1016" target="_blank">1016 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016" target="_blank">1016 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>HET</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/msd-srv/chempdb/cgi-bin/cgi.pl?FUNCTION=getByCode&amp;CODE=OHT" target="_blank">OHT <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2237460" target="_blank">2237460 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/tamox.htm" target="_blank">http://www.rxlist.com/cgi/generic/tamox.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/tamoxifen.html" target="_blank">http://www.drugs.com/tamoxifen.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Tamoxifen" target="_blank">Tamoxifen <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>L02BA01<ul class="atc-drug-tree"><li><a href="/atc/L#L">L &#8212; ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</a></li><li><a href="/atc/L02#L02">L02 &#8212; ENDOCRINE THERAPY</a></li><li><a href="/atc/L02B#L02B">L02B &#8212; HORMONE ANTAGONISTS AND RELATED AGENTS</a></li><li><a href="/atc/L02BA#L02BA">L02BA &#8212; Anti-estrogens</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>10:00.00</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00675.pdf?1265922814">show</a>(102 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00675.pdf?1265922750">show</a>(74.8 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Tamoxifen may increase the serum concentration of Acenocoumarol increasing the risk of bleeding. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00357">Aminoglutethimide</a></td><td>Aminoglutethimide may increase Tamoxifen clearance decreasing its therapeutic effect. Consider alternate therapy or monitor for changes in Tamoxifen effects when Aminoglutethimide is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Amiodarone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB01101">Capecitabine</a></td><td>Capecitabine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Capecitabine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00608">Chloroquine</a></td><td>Chloroquine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Chlorpromazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01012">Cinacalcet</a></td><td>Cinacalcet may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Clarithromycin may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Clomipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Clozapine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00907">Cocaine</a></td><td>Cocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Conivaptan may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB00496">Darifenacin</a></td><td>Darifenacin may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01264">Darunavir</a></td><td>Darunavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Delavirdine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Desipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01075">Diphenhydramine</a></td><td>Diphenhydramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00476">Duloxetine</a></td><td>Duloxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00322">Floxuridine</a></td><td>Floxuridine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Floxiridine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconzole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluconazole  is initiated, discontinued or dose changed.
</td></tr><tr><td><a href="/drugs/DB00544">Fluorouracil</a></td><td>Fluorouracil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluorouracil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Fluoxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00712">Flurbiprofen</a></td><td>Flurbiprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Flurbiprofen is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Fosmprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>Gemfibrozil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Gemfibrozil  is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Haloperidol may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>Ibuprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Ibuprofen is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Imatinib may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Imatinib may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Imatinib is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Imipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>Indomethacin may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Indomethacin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Isoniazid may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Isoniazid may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Isoniazid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Ketoconazole may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00281">Lidocaine</a></td><td>Lidocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB01601">Lopinavir</a></td><td>Lopinavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Lumefantrine, a moderate CYP2D6 inhibitor, may decrease the formation of highly potent tamoxifen metabolites. Concomitant therapy may decrease the effectiveness of tamoxifen. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00784">Mefenamic acid</a></td><td>Mefenamic acid may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Mefenamic acid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>Methadone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00763">Methimazole</a></td><td>Methimazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB01110">Miconazole</a></td><td>Miconazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Nefazodone may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB00622">Nicardipine</a></td><td>Nicardipine may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Nicardipine may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Nicardipine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB04868">Nilotinib</a></td><td>Nilotinib may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Paroxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01186">Pergolide</a></td><td>Pergolide may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01132">Pioglitazone</a></td><td>Pioglitazone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00554">Piroxicam</a></td><td>Piroxicam may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Piroxicam is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Posaconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB00205">Pyrimethamine</a></td><td>Pyrimethamine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Quinidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00468">Quinine</a></td><td>Quinine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Ranolazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>The rifamycin decreases the effect of anti-estrogen</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>The rifamycin decreases the effect of anti-estrogen</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB06228">Rivaroxaban</a></td><td>Tamoxifen may increase serum concentrations of Rivaroxaban increasing the risk of bleeding. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Saquinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>Sertraline may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB06268">Sitaxentan</a></td><td>Sitaxsentan may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sitaxsentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00359">Sulfadiazine</a></td><td>Sulfadiazine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfadiazine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00263">Sulfisoxazole</a></td><td>Sulfisoxazole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfisoxazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Tamoxifen. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tamoxifen if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Thioridazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine may decrease the therapeutic effect of tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tamoxifen. Consider alternate therapy or monitor for changes in Tamoxifen therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Tamoxifen, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>The CYP2D6 inhibitor, Tranylcypromine, may decrease the efficacy of Tamoxifen by reducing active metabolite production. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Trazodone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The moderate CYP2C8 inhibitor, Tamoxifen, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Tamoxifen is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamoxifen by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamoxifen if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Tamoxifen, a CYP2C9 inhibitor, may increase the serum concentration of warfarin by decreasing its metabolism. Concomitant therapy is contraindicated due to significant increase in bleed risk.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>